Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses

R. H. Earhart, J. M. Koeller, H. L. Davis

    Research output: Contribution to journalArticlepeer-review

    22 Scopus citations

    Abstract

    6-Diazo-5-oxo-L-norleucine (DON), an L-glutamine antagonist, was administered to 25 evaluable patients with refractory advanced solid tumors in a phase I trial. A total of 58 evaluable courses of five daily iv injections every 3-4 weeks were given, at doses ranging from 7.5 to 90 mg/m2/day. The major dose-limiting toxicity was a syndrome of nausea, vomiting, malaise, and anorexia, which became severe at doses > 52.5 mg/m2/day. Diarrhea and stomatitis were less frequent. Hematologic toxicity included mild leukopenia with nadir on Day 6-8 and mild thrombocytopenia with nadir on Day 7-12. Transient decrease in serum calcium to 8.5-8.9 mg/dl were seen in seven of 12 patients receiving ≥67.5 mg/m2/day. Dose reduction was required for all patients who received a course of DON at > 67.5 mg/m2/day, and a maximum tolerated total dose of 250 mg/m2 (50 mg/m2/day x 5) is suggested for this schedule. Mixed responses were seen in one patient with bladder carcinoma and in one with pulmonary adenocarcinoma.

    Original languageEnglish (US)
    Pages (from-to)1215-1217
    Number of pages3
    JournalCancer Treatment Reports
    Volume66
    Issue number5
    StatePublished - Jan 1 1982

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses'. Together they form a unique fingerprint.

    Cite this